A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy

Sponsor
The Affiliated Hospital of Qingdao University
Study ID
NCT07676266
Phase
PHASE1
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • CD20/BCMA-directed CAR-T cells Autologous 2nd generation — BIOLOGICAL
    CD20/BCMA-directed CAR-T cells, single infusion intravenously

Study Details

This is an investigator-initiated, single-center, open-label study of C-CAR168, an autologous bi-specific CAR-T therapy targeting CD20 and BCMA, for the treatment of adult patients with autoimmune diseases refractory to standard therapy

Key Dates

Start date
Jul 31, 2026
Status verified
Jun 2026
Primary completion
Nov 30, 2027
Completion
Oct 31, 2028

Study Design

Enrollment
18 participants (estimated)
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: C-CAR168 Autologous C-CAR168 administered by intravenous (IV) infusion

Primary Outcome Measure

Incidence and severity of Adverse Events [Safety and Tolerability] [ Time Frame: Throughout the first 3 months follow up period completion ]

Central Contacts

Related Studies